testicular carcinoma: A primary or metastatic malignant neoplasm that affects the testis. Representative examples include seminoma, embryonal carcinoma, sarcoma, leukemia, and lymphoma.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleonly males |
244368 |
2. Check conditionsNone |
244368 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
131 |
4. Check minimum number of eventsNone |
131 |
5. Include endpointsNone |
131 |
6. Filter based on genotype QC (FinnGen only) |
119 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D29
- Name in latin
- Neoplasma benignum epididymidis
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Epididymis
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm of male genital organs
- Benign neoplasms
- Neoplasms
- Any operation in hilmo
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 908 | - | 908 |
| Only index persons | 837 | - | 837 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | - | 0.03 |
| Only index persons | 0.03 | - | 0.03 |
| Median age at first event (years) | |||
| Whole population | - | - | 51.60 |
| Only index persons | - | - | 50.67 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 119 | - | 119 |
| Unadjusted period prevalence (%) | 0.05 | - | 0.05 |
| Median age at first event (years) | 54.16 | - | 54.16 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 125
- Matched controls
- 1250
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D29.3
ICD-10 Finland
Benign neoplasm: Epididymis
+∞
140.5
107
*
KFD16
NOMESCO Finland
Partial excision of epididymis
108.5
24.7
26
*
2223A
ICD-9 Finland
Benign neoplasm of male genital organs, Epididymis
+∞
19.3
18
*
KF8AE
NOMESCO Finland
Ultrasound examination of scrotum
11.3
13.3
25
27
D40.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Testis
35.9
10.6
13
*
N43.4
ICD-10 Finland
Spermatocele
8.9
8.7
18
23
D40.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other male genital organs
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
72
503
2.02
3.59
5.9
8.3
1.21
1.20
mmol/l
0.58
62
445
103
868
2.06
2.47
3.9
4.2
1.80
2.05
mu/l
1.11
97
790
6
13
4.79
2.30
1.3
2.5
—
—
—
0
0
116
1048
2.48
2.22
21.3
21.0
4.00
4.04
mmol/l
0.73
116
1034
6
14
4.44
2.18
1.3
2.4
—
—
—
0
0
46
316
1.72
2.14
3.6
3.0
2.43
0.51
e6/l
0.58
33
234
94
785
1.80
2.10
5.9
5.1
1.89
2.29
ug/l
0.40
83
709
61
469
1.59
1.75
2.6
2.9
—
—
estimate
—
0
0
117
1078
2.33
1.75
23.2
23.1
89.21
87.23
umol/l
0.38
117
1072
115
1046
2.24
1.69
21.4
20.9
139.50
139.58
mmol/l
0.09
115
1032
113
1027
2.04
1.57
16.4
17.3
28.61
28.02
mg/l
0.06
98
862
70
579
1.47
1.31
2.4
2.8
—
—
—
0
0
118
1108
2.16
1.31
26.0
26.2
140.99
140.68
g/l
0.07
118
1099
118
1107
2.18
1.31
25.9
26.1
218.81
231.98
e9/l
1.73
118
1088
118
1107
2.18
1.31
26.9
26.7
41.87
41.60
%
0.25
118
1097
118
1107
2.18
1.31
25.7
26.1
91.29
91.14
fl
0.13
118
1099
118
1107
2.18
1.31
25.8
26.1
4.64
4.65
e12/l
0.06
118
1085
53
422
1.44
1.18
2.2
2.2
78.01
93.40
pmol/l
2.10
33
230
107
979
1.65
1.13
5.5
5.3
5.90
6.23
mmol/l
2.22
99
909
28
198
1.53
1.11
2.6
2.7
2.76
0.81
e6/l
0.60
14
111
26
182
1.54
1.07
3.0
2.8
0.92
0.47
e6/l
0.35
12
95
69
584
1.41
1.06
7.9
11.4
4.58
4.26
e9/l
0.27
64
514
91
811
1.45
1.03
8.3
8.9
76.59
80.38
u/l
0.51
86
786
56
464
1.37
0.95
4.1
4.0
17.47
48.58
ng/l
3.20
46
361
62
528
1.35
0.87
4.3
3.8
0.00
0.00
estimate
-0.00
11
108
38
301
1.38
0.84
3.8
3.2
0.13
0.01
estimate
—
8
92
72
630
1.34
0.83
4.9
4.3
20.19
22.53
%
0.65
34
298
56
473
1.33
0.81
3.8
3.0
0.74
0.72
ug/l
0.06
34
301
50
417
1.33
0.79
1.8
2.0
1.45
1.47
mmol/l
0.05
43
351
0
27
0.00
0.78
0.0
1.1
—
—
—
0
0
33
259
1.37
0.76
1.8
2.1
2.95
2.93
mg/l
0.02
28
230
42
346
1.32
0.71
4.6
2.9
60.00
70.96
u/l
0.37
37
326
10
61
1.69
0.71
2.3
1.8
—
—
—
0
0
60
522
1.29
0.68
4.5
3.8
0.00
0.00
estimate
-0.00
11
110
9
137
0.63
0.65
1.2
1.4
—
—
—
0
0
61
536
1.27
0.62
4.3
3.8
0.00
0.00
estimate
—
9
96
15
206
0.69
0.62
1.3
1.4
0.98
1.11
u/ml
—
8
68
0
20
0.00
0.61
0.0
1.4
—
—
—
0
0
0
20
0.00
0.61
0.0
1.1
—
—
—
0
0
0
21
0.00
0.60
0.0
1.1
—
—
—
0
0
10
66
1.56
0.54
2.0
2.0
—
—
—
0
0
19
146
1.36
0.51
8.8
9.0
4.77
5.01
kpa
0.86
19
138
19
146
1.36
0.51
8.8
9.0
12.62
11.59
kpa
0.36
19
140
30
250
1.26
0.46
2.5
2.5
—
—
—
0
0
106
1012
1.31
0.45
5.3
5.3
1.32
1.30
mmol/l
0.32
101
939
0
15
0.00
0.41
0.0
1.5
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
5
34
1.49
0.41
1.2
1.3
—
—
—
0
0
0
18
0.00
0.40
0.0
4.6
—
—
—
0
0
5
35
1.45
0.40
1.6
2.1
—
—
—
0
0
44
389
1.20
0.39
2.0
2.4
70.53
71.84
nmol/l
0.11
38
350
0
19
0.00
0.39
0.0
1.3
—
—
—
0
0
9
67
1.37
0.39
1.1
2.2
211.89
225.47
pmol/l
—
9
62
5
36
1.40
0.38
1.0
1.7
—
—
—
0
0
9
71
1.29
0.37
2.7
3.4
24.83
23.90
mmol/l
—
9
71
46
412
1.18
0.35
4.4
3.8
0.00
0.03
estimate
—
9
99
24
202
1.23
0.34
1.7
2.1
—
—
—
0
0
10
74
1.38
0.33
2.5
2.7
1.43
1.49
%
—
10
74
14
110
1.31
0.33
11.1
9.1
1.53
1.43
mmol/l
0.08
14
110
103
990
1.23
0.33
4.7
4.6
1.34
1.37
mmol/l
0.19
97
915
17
207
0.79
0.33
5.5
3.9
0.80
0.82
mmol/l
0.28
17
197
21
176
1.23
0.31
9.2
8.1
104.90
104.51
mmol/l
0.13
21
176
10
75
1.36
0.31
11.1
9.2
25.94
24.27
mmol/l
—
10
75
18
154
1.20
0.22
1.5
2.0
—
—
—
0
0
0
11
0.00
0.21
0.0
2.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
2.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
10
80
1.27
0.21
2.1
2.8
71.20
61.21
ml/min/173m2
—
5
34
0
14
0.00
0.20
0.0
1.0
—
1.48
—
0
5
37
401
0.89
0.19
5.8
4.6
4.99
12.09
mg/mmol
1.63
25
284
13
109
1.22
0.19
2.5
3.1
4.23
4.62
kpa
0.35
13
103
95
978
0.88
0.19
7.6
7.2
39.92
40.84
mmol/mol
0.50
90
933
15
128
1.20
0.19
2.5
4.3
5.95
5.69
kpa
0.58
15
122
7
61
1.16
0.18
1.6
1.9
—
—
—
0
0
7
88
0.78
0.15
1.4
1.4
—
—
—
0
0
7
89
0.77
0.15
1.4
1.8
—
—
—
0
0
10
117
0.84
0.13
2.7
3.2
—
—
—
0
0
13
148
0.86
0.13
1.5
2.1
—
—
—
0
0
75
728
1.08
0.11
3.3
3.8
51.42
57.00
u/l
0.28
69
694
5
43
1.17
0.10
1.2
2.3
—
—
—
0
0
12
109
1.11
0.06
5.9
9.0
—
—
—
0
0
24
230
1.05
0.04
1.5
1.6
1.34
1.68
mg/l
0.31
19
181
31
303
1.03
0.01
4.7
3.9
0.00
0.03
estimate
—
10
97
12
124
0.96
0.00
1.8
1.3
1.41
5.39
u/ml
—
7
46
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
73.12
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
76
0.92
-0.00
4.9
2.8
0.03
2.24
mmol/l
—
7
58
0
5
0.00
-0.00
0.0
1.0
—
40.40
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
113.02
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
10.45
—
0
6
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
1026.00
—
0
5
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
25.94
—
0
5
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
5
57
0.87
-0.00
1.0
2.2
0.42
1.01
ug/l
—
5
51
0
5
0.00
-0.00
0.0
4.4
—
76.20
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CD2_BENIGN_EPIDIDYMIS and mortality.
Females
No dataMales
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_EPIDIDYMIS | 0.951 [0.75, 1.2] | 0.673 |
| Birth year | 0.985 [0.98, 0.99] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 98 out of 637 males with CD2_BENIGN_EPIDIDYMIS died.
Mortality risk
Mortality risk for people of age
years, who have CD2_BENIGN_EPIDIDYMIS.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | 0.15% |
| 5 | No data | 1.044% |
| 10 | No data | 2.681% |
| 15 | No data | 5.038% |
| 20 | No data | 8.452% |
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_EPIDIDYMIS – Benign neoplasm: Epididymis
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data